Clinical trial
Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent…
NCT00362882 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00362882 |
|---|---|
| Title | Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer |
| Official title | Randomized Phase II Trial of Sequential Versus Concurrent Docetaxel and PS-341 (NSC 681239) in Previously Treated Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer |
| Intervention type | Drug, Other |
| Interventions | docetaxel, bortezomib, laboratory biomarker analysis, immunoenzyme technique, immunohistochemistry staining method, pharmacological study |
| Enrollment | 81 |
| Start date | Jul 1, 2006 |
| Primary completion | Jul 1, 2010 |
| Completion | Jul 1, 2010 |
| First posted | Aug 15, 2006 |
| Last update posted | Dec 5, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: